Climb Bio (CLYM) versus Its Competitors Critical Survey

Climb Bio (NASDAQ:CLYM) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Climb Bio to related companies based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings for Climb Bio and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7744	21123	48811	1224	2.55

Climb Bio presently has a consensus price target of $10.00, indicating a potential upside of 313.22%. As a group, “Pharmaceutical preparations” companies have a potential upside of 184.71%. Given Climb Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Climb Bio is more favorable than its peers.

Profitability

This table compares Climb Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Valuation & Earnings

This table compares Climb Bio and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-1.14
Climb Bio Competitors	$2.20 billion	$150.62 million	-5.46

Climb Bio’s peers have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Climb Bio has a beta of -0.4, meaning that its stock price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s peers have a beta of 3.71, meaning that their average stock price is 271% more volatile than the S&P 500.

Summary

Climb Bio beats its peers on 7 of the 13 factors compared.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.